NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. More Details
Flawless balance sheet with questionable track record.
Share Price & News
How has NGL Fine-Chem's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 524774's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 524774 exceeded the Indian Pharmaceuticals industry which returned 48.6% over the past year.
Return vs Market: 524774 exceeded the Indian Market which returned 2.6% over the past year.
Price Volatility Vs. Market
How volatile is NGL Fine-Chem's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Is NGL Fine-Chem undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 524774 (₹886) is trading above our estimate of fair value (₹50.39)
Significantly Below Fair Value: 524774 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 524774 is poor value based on its PE Ratio (43.7x) compared to the IN Pharmaceuticals industry average (22.8x).
PE vs Market: 524774 is poor value based on its PE Ratio (43.7x) compared to the Indian market (16.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 524774's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 524774 is overvalued based on its PB Ratio (5.5x) compared to the IN Pharmaceuticals industry average (2.2x).
How is NGL Fine-Chem forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NGL Fine-Chem has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine NGL Fine-Chem's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- NGL Fine-Chem competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has NGL Fine-Chem performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 524774 has high quality earnings.
Growing Profit Margin: 524774's current net profit margins (8.2%) are lower than last year (12.8%).
Past Earnings Growth Analysis
Earnings Trend: 524774's earnings have grown by 7.9% per year over the past 5 years.
Accelerating Growth: 524774's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 524774 had negative earnings growth (-38.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.7%).
Return on Equity
High ROE: 524774's Return on Equity (12.7%) is considered low.
How is NGL Fine-Chem's financial position?
Financial Position Analysis
Short Term Liabilities: 524774's short term assets (₹808.6M) exceed its short term liabilities (₹430.4M).
Long Term Liabilities: 524774's short term assets (₹808.6M) exceed its long term liabilities (₹116.2M).
Debt to Equity History and Analysis
Debt Level: 524774's debt to equity ratio (28.5%) is considered satisfactory.
Reducing Debt: 524774's debt to equity ratio has reduced from 40.6% to 28.5% over the past 5 years.
Debt Coverage: 524774's debt is well covered by operating cash flow (72.5%).
Interest Coverage: 524774's interest payments on its debt are well covered by EBIT (8.6x coverage).
What is NGL Fine-Chem current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 524774's dividend (0.2%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.55%).
High Dividend: 524774's dividend (0.2%) is low compared to the top 25% of dividend payers in the Indian market (2.28%).
Stability and Growth of Payments
Stable Dividend: 524774 is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.
Growing Dividend: 524774 is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: 524774 is not paying a notable dividend for the Indian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 524774's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Rahul Nachane (56 yo)
Mr. Rahul Jayant Nachane, B. Com, ACA, MMS, DBF has been Managing Director of NGL Fine-Chem Ltd. since June 1, 2006 and serves as its Chief Executive Officer. Mr. Nachane serves as the Chief Ethics Counse ...
CEO Compensation Analysis
Compensation vs Market: Rahul's total compensation ($USD167.19K) is above average for companies of similar size in the Indian market ($USD55.56K).
Compensation vs Earnings: Rahul's compensation has been consistent with company performance over the past year.
|CEO, MD||no data||₹12.34m||17.54% |
|Whole Time Director & CFO||15.33yrs||₹12.20m||21.89% |
|Independent Chairman||no data||₹245.00k||no data|
|Non Executive Woman Director||6.08yrs||₹225.00k||11.55% |
|Independent Non-Executive Director||5.17yrs||₹240.00k||0.38% |
|Non-Executive Independent Director||0.67yr||no data||no data|
Experienced Board: 524774's board of directors are considered experienced (6.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
NGL Fine-Chem Limited's company bio, employee growth, exchange listings and data sources
- Name: NGL Fine-Chem Limited
- Ticker: 524774
- Exchange: BSE
- Founded: 1981
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹5.474b
- Shares outstanding: 6.18m
- Website: https://www.nglfinechem.com
Number of Employees
- NGL Fine-Chem Limited
- 301, E Square
- Subhash Road
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|524774||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||Dec 2004|
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. The company offers active pharmaceutical ingredients, such as diminazene ace ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/24 12:40|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.